GENE (Genetic Technologies) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Dec. 15, 2024)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Genetic Technologies's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Genetic Technologies's Future 3-5Y EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Genetic Technologies's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's Future 3-5Y EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Future 3-5Y EPS without NRI Growth Rate falls into.

Genetic Technologies (NAS:GENE) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Genetic Technologies Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

0A4N:UK DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.